Techne, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $297.03 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 4.11%.
Keybank National Association OH boosted its position in shares of Bio-Techne Co. (NASDAQ:TECH – Free Report) by 66.4% in the ...
Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific ...
TECHNE is a practice-based digital arts research initiative founded by Professor Mark Amerika, at the University of Colorado at Boulder. The TECHNE initiative develops innovative approaches to the ...
Argus analyst David Toung lowered the firm’s price target on Bio-Techne (TECH) to $90 from $95 and keeps a Buy rating on the shares after its Q2 earnings beat earlier this month. The company’s ...
Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Bio-Techne by 46.6% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 16,650 shares of the ...
The $40m tower proposal was granted a planning permit by the Hobart City Council last year and the proponent, Techne Invest, which counts former AFL star Nick Riewoldt as one of its directors ...
Citi lowered the firm’s price target on Bio-Techne (TECH) to $70 from $80 and keeps a Neutral rating on the shares. The firm updated models in the life science tools and diagnostics group post ...
MINNEAPOLIS and OXFORD, England, March 3, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, a Bio-Techne brand, has teamed up with Oxford Nanopore ...
(RTTNews) - Bio-Techne Corp. (TECH) announced earnings for its second quarter that increased from last year and beat the Street estimates. The company's bottom line totaled $34.89 million ...
Headquartered in Minneapolis, Minnesota, Bio-Techne Corporation (TECH) is a leading provider of life sciences solutions dedicated to advancing biomedical research and diagnostics. With a market ...